Safety and Efficacy of Bortezomib in addition to Adriamycin [doxorubicin] and Intermediate-Dose Dexamethasone (iPAD) in Subjects with Relapse/Refractory Multiple Myeloma with Primary Therapies; A PhaseI/II, Multicentre, Open-Label, Single-Arm Study
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2018
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Apr 2011 Status changed from recruiting to completed, according to the University Hospital Medical Information Network - Japan.
- 27 Jun 2008 New trial record.